Agios Pharmaceuticals | AGIO - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Astellas Pharma JPY 48.02B 85.93B 2026-03
AstraZeneca USD 3.91B 1.28B 2026-03
Bayer EUR -1.16B 735M 2025-09
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09